Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-01-11
2011-12-13
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387100
Reexamination Certificate
active
08075884
ABSTRACT:
This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
REFERENCES:
patent: 3940475 (1976-02-01), Gross
patent: 4289747 (1981-09-01), Chu
patent: 4376110 (1983-03-01), David et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5508717 (1996-04-01), Miller
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5780279 (1998-07-01), Matthews et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5902583 (1999-05-01), Buchsbaum et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6040136 (2000-03-01), Garrard et al.
patent: 6338851 (2002-01-01), Gorczynski
patent: 6632927 (2003-10-01), Adair et al.
patent: 6652858 (2003-11-01), Gorczynski et al.
patent: 6737056 (2004-05-01), Presta
patent: 6749854 (2004-06-01), Gorczynski et al.
patent: 6955811 (2005-10-01), Gorczynski et al.
patent: 6984625 (2006-01-01), Gorczynski
patent: 7238352 (2007-07-01), Gorczynski et al.
patent: 2002/0031515 (2002-03-01), Caligiuri et al.
patent: 2002/0168336 (2002-11-01), Ng et al.
patent: 2002/0168364 (2002-11-01), Gorczynski et al.
patent: 2002/0192215 (2002-12-01), Hoek et al.
patent: 2003/0017491 (2003-01-01), Shi et al.
patent: 2004/0018972 (2004-01-01), Gorczynski et al.
patent: 2004/0054145 (2004-03-01), Gorczynski
patent: 2004/0175692 (2004-09-01), Bowdish et al.
patent: 2004/0198661 (2004-10-01), Bowdish et al.
patent: 2005/0048069 (2005-03-01), Gorczynski et al.
patent: 2005/0107314 (2005-05-01), Gorczynski et al.
patent: 2005/0129690 (2005-06-01), Bowdish et al.
patent: 2005/0169870 (2005-08-01), Truitt et al.
patent: 2006/0024231 (2006-02-01), Schnitzer et al.
patent: 2008/0131428 (2008-06-01), Young et al.
patent: WO-84/03508 (1984-09-01), None
patent: WO-8403508 (1984-09-01), None
patent: WO-85/03508 (1985-08-01), None
patent: WO-8503508 (1985-08-01), None
patent: WO-88/06630 (1988-09-01), None
patent: WO-92/15679 (1992-09-01), None
patent: WO-9215679 (1992-09-01), None
patent: WO-94/28027 (1994-12-01), None
patent: WO-9428027 (1994-12-01), None
patent: WO-95/18825 (1995-07-01), None
patent: WO-9518825 (1995-07-01), None
patent: WO-96/27011 (1996-09-01), None
patent: WO-9627011 (1996-09-01), None
patent: WO-96/38557 (1996-12-01), None
patent: WO 9638557 (1996-12-01), None
patent: WO-97/08320 (1997-03-01), None
patent: WO-9708320 (1997-03-01), None
patent: WO-97/21450 (1997-06-01), None
patent: WO-9721450 (1997-06-01), None
patent: WO-8806630 (1998-09-01), None
patent: WO-99/24565 (1999-05-01), None
patent: WO-9924565 (1999-05-01), None
patent: WO-01/87336 (2001-11-01), None
patent: WO-02/11762 (2002-02-01), None
patent: WO-0211762 (2002-02-01), None
patent: WO-02/42332 (2002-05-01), None
patent: WO-0242332 (2002-05-01), None
patent: WO-02/059280 (2002-08-01), None
patent: WO-02/095030 (2002-11-01), None
patent: WO-02095030 (2002-11-01), None
patent: WO-03/025202 (2003-03-01), None
patent: WO-03025202 (2003-03-01), None
patent: WO 2004/060295 (2004-07-01), None
patent: WO-2004/078937 (2004-09-01), None
patent: WO-2004/078938 (2004-09-01), None
patent: WO-2004078937 (2004-09-01), None
patent: WO-2006/053301 (2006-05-01), None
patent: WO 2007/084321 (2007-07-01), None
Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, 79: 1979-1983.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.
Simelyte et al., “CD200-Fc, a Novel Antiarthritic Biologic Agent That Targets Proinflammatory Cytokine Expression in the Joints of Mice With Collagen-Induced Arthritis,” Arthritis & Rheumatism, vol. 58(4), pp. 1038-1043 (2008).
Alizadeh et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, 403:503-511(2000).
Auchincloss et al. “Strategies to Induce Tolerance,” Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).
Bach, “Immunosuppressive therapy of autoimmune diseases,” Immunology Today, 14(6)322-326(1993).
Banerjee, D., et al., “Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats,” Ocular Immunology and Inflammation, 12(2):115-125 (2004).
Barclay and Ward, “Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2,” European J. Biochemistry, 129:447-458(1982).
Barclay et al.,“CD200 and membrane protein interactions in the control of myeloid cells,” Trends in Immunology, 23(6):2002.
Barclay, A.N., “Different reticular elements in rat lymphoid tissue identified by localization of la, Thy-1 and MRC OX 2 antigens,” Immunology, 44:727-736 (1981).
Barclay, A.N., et al., “Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure,” Biochem. Soc. Symp., 51:149-157 (1985).
Bauvois et al., Constitutive expression of CD26/dipeptidylpepidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. British Journal of Cancer 1999., vol. 79. p. 1042.
Blazer, B.R., et al., “CD28/B7 Interactions Are Required for Sustaining the Graft-Versus-Leukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells,” J. Immunol., 159:3460-3473 (1997).
Bodey et al. “Human Cancer Detection and Immunotherapy with Conjugated and Non-Conjugated Monoclonal Antibodies” Anticancer Research 16: 661-674 (1996).
Bohen, S.P., “Variation in gene expression patterns in follicular lymphoma and the response to rituximab,” PNAS, 100(4):1926-1930(2003).
Boon, Thierry., “Toward a Genetic Analysis of Tumor Rejection Antigens,” Advances in Cancer Res., 58:177-210(1992).
Borriello et al., “MRC OX-2 Defines a Novel T Cell Costimulatory Pathway,” J. Immunol., 158:4549-4554(1997).
Borriello, F., et al., “Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX—2 membrane glycoprotein,” Mammalian Genome, 9(2):114-118 (1998).
Broderick et al., “Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis,” Am. J. of Pathology, 161(5):1669-1677(2002).
Bukovsky, A., et al., “Association of lymphoid cell markers with rat ascitic malignant cells,” IRCS Med. Sci., 11:866-867 (1983).
Bukovsky, A., et al., “Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy,” Immunology, 52:631-640 (1984).
Bukovsky, A., et al., “The localization of Thy-1.1, MRC OX 2 and la antigens in the rat ovary and follopian tube,” Immunology, 48:587-596 (1983).
Bukovsky, A., et al., “The ovarian follicle as a model for the cell-mediated control of tissue growth,” Cell Tissue Res., 236:717-724 (1984).
Caldas et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,” Mol. Immunol. 39:941-952 (2003).
Chaouat and Clark, FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer. J. of Reprod. Immunol., 45:108-115(2001).
Chen, D., et al., “Discrete Monoclonal Antibodies Define Functionally Important Epitopes in the CD200 Molecule Responsible for Immunosupression Function,” Transplantation, 79:282-288 (2005).
Chen, D., et al., “Synthetic peptides from the N-terminal regionsl of CD200
Bowdish Katherine S.
Faas McKnight Susan
Kretz-Rommel Anke
Springhorn Jeremy P.
Wu Dayang
Alexion Pharmaceuticals, Inc.
Ouspenski Ilia
Ropes & Gray LLP
LandOfFree
Antibodies to OX-2/CD200 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to OX-2/CD200 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to OX-2/CD200 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300127